In particular, the recent clinical studies showed that the R/R MM patients resistant to anti-BCMA CAR-T cell therapy could also benefit from selinexor-based regimens and carfilzomib-based regimens (227, 228), and a study reported that anti-BCMA CAR-T cell therapy combined with lenalidomide was effective in the R/R MM patients who had previously relapsed after anti-BCMA CAR-T cell therapy (229). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.